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Physiotherapy rehabilitation for people with progressive Multiple Sclerosis: a systematic 
review. 
 
Abstract 
 
Objective: To assess the efficacy of physiotherapy interventions, including exercise therapy, 
for the rehabilitation of people with progressive Multiple Sclerosis. 
Data Sources: Five databases (Cochrane Library, Physiotherapy Evidence Database (PEDro), 
Web of Science Core Collections, Medline, EMBASE) and reference lists of relevant articles 
were searched.   
Study Selection: Randomised experimental trials which included participants with 
progressive multiple sclerosis and investigated a physiotherapy intervention or an 
intervention containing a physiotherapy element were included. 
Data Extraction: Data were independently extracted using a standardised form and 
methodological quality was assessed using the PEDro scale. 
Data Synthesis: Thirteen studies (described by 15 articles) were identified; scoring between 
5 and 9 out of 10 on the PEDro scale. Eight interventions were assessed: exercise therapy, 
multi-disciplinary rehabilitation, functional electrical stimulation, botulinum toxin type A 
injections and manual stretches, inspiratory muscle training, therapeutic standing, 
acupuncture and body weight supported treadmill training. All studies, apart from one, 
produced positive results in at least one outcome measure, however, only one article used a 
power calculation to determine their sample size and due to ‘drop outs’ the results were 
subsequently underpowered. 
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Conclusions: This review suggests that physiotherapy may be effective for the rehabilitation 
of people with progressive Multiple Sclerosis. However, further appropriately powered 
studies are required. 
Keywords: Multiple Sclerosis, physical therapy modalities, exercise, rehabilitation, review  
 
List of abbreviations 
BTX-A  botulinum toxin type A 
BWSTT  body weight supported treadmill training 
EDSS  expanded disability status scale 
FES  functional electrical stimulation 
MCID  minimal clinically important difference 
MeSH  medical subject headings 
MS  multiple sclerosis 
PEDro  Physiotherapy Evidence Database 
PPMS  primary progressive multiple sclerosis  
RRMS  relapsing remitting multiple sclerosis 
SPMS  secondary progressive multiple sclerosis  
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Multiple Sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease of the 
central nervous system resulting in grey matter and axonal loss.1, 2 Currently, there are an 
estimated 130,000 cases of MS in the UK with an incidence of 11.52 per 100,000 women 
and 4.84 per 100,000 men.3 Approximately 15% of all individuals with MS are diagnosed 
with Primary Progressive MS (PPMS) and 80% of those diagnosed with Relapsing Remitting 
MS (RRMS) go on to develop Secondary Progressive MS (SPMS).4 There is a strong evidence 
base for interventions for the treatment of people with RRMS but whilst studies are 
currently ongoing there are limited effective treatments for people with progressive MS.5 
The Progressive MS Alliance have highlighted this area as a priority, especially for those with 
a higher level of disability.5   
There is a growing body of literature investigating the benefits of physiotherapy (a physical 
intervention that may be used by a physiotherapist, including physical activity and exercise 
interventions) in the rehabilitation of people with MS. In a series of review papers, exercise 
therapy and physical activity have been shown to be generally beneficial to those with MS 
who are not suffering a relapse,6-8 as well as having positive effects on fatigue,9, 10 health 
related quality of life11 and muscle strength12 in those with a mild to moderate disability. 
Physiotherapy has also been shown to have a positive effect on balance and mobility.13-15 
However, when the level of disability increases efficacy of physiotherapy is less 
compelling.13, 15 Whilst some studies have considered their results in terms of disability 
levels, none have made a distinction between RRMS and progressive MS. To date, there has 
not been a published review examining the evidence for physiotherapy for the rehabilitation 
of people with progressive MS. Consequently, the aim of this systematic review is to assess 
the efficacy of physiotherapy rehabilitation for people with progressive MS. 
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Methods  
 
In December 2014 a search was conducted of the following electronic databases: the 
Cochrane Library, Physiotherapy Evidence Database (PEDro), Web of Science Core 
Collections, Medline and Embase. No restrictions were placed on publication date and 
studies were limited to English language only. Individual search strategies were made up of 
keywords and Medical Subject Headings (MeSH) headings (Table 1). Reference lists of 
relevant articles were also searched. 
To be included in the review, articles had to; be published in English, include solely 
participants with progressive forms of MS or where there was a combination of types of MS 
distinct results for the different types of MS are presented, evaluate a physiotherapy 
intervention(s) or an intervention containing a physiotherapy element, have randomised 
participants, have a comparison group and use at least one objective outcome measure. 
Articles were excluded if they were non-human studies, conference abstracts or posters. 
Articles were initially screened by title and abstract. Full articles were then read. When 
there was ambiguity in meeting the inclusion criteria the authors were contacted for 
clarification.  
Quality assessment (external validity, internal validity and the reporting of statistics) was 
assessed using the PEDro scale which has been shown to be reliable and valid in rating 
methodological quality of studies.16, 17 The 11 point scale was given a score out of ten (no 
point was awarded for the initial item of stating inclusion and exclusion criteria) as per the 
Physiotherapy for progressive MS 
6 
 
guidelines. Scoring was carried out by three reviewers (EC, LP and EHC). A pilot quality 
assessment was conducted to ensure consistency where all three reviewers read and 
independently scored one paper, following which, scoring was discussed and agreed.  Each 
article was then scored independently by two reviewers and scores compared. When there 
was a discrepancy in score, differences were agreed via discussion which included the third 
reviewer. Quality assessment was entirely based on the content of the study in the 
published article. When two articles were from the same study but reported different 
outcome measures they were combined and considered as a single study. Data extraction 
was done independently using a standardised form into evidence tables. The following data 
were extracted: study design, sample size, drop-out rate, type of MS of participants, 
Expanded Disability Status Scale (EDSS) range,18 intervention type, length, frequency, 
setting, time points of measurement, control intervention, outcome measures, baseline 
measurements and  main findings. 
 
Results 
 
Outcome of search 
 
From the electronic search 1027 articles were identified and four articles were identified 
from relevant article’s reference lists (Figure 1). Of these, 197 were duplicates leaving 834 
unique publications for screening by title and abstract. After screening 783 articles were 
excluded. Full texts of 51 articles were read and 36 were excluded. From the remaining 15 
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articles; there were two instances of two papers that were from the same study but had 
used different outcome measures and so they were combined.19-22 Thus 13 studies 
(published within 15 articles) were included within this review (Figure 1).   
 
Quality assessment, study design and sample characteristics 
 
PEDro scores ranged from 5-9 out of 10 (Table 2). Lower scores were mainly due to lack of 
blinding of patients, therapists or assessors and not conducting analyses with intention to 
treat when appropriate. Only one article19 supplied a power calculation used to determine 
their sample size but due to ‘drop outs’ the results were subsequently underpowered. From 
the remaining studies, six highlighted their lack of power calculation23-28 and four 
highlighted their small sample size29-32 as methodological limitations; two studies did not 
mention either a power calculation or comment on their sample size.21, 22, 33 
 
From the studies included in the review there were nine randomised controlled trials 
(described in 11 articles),19-22, 24, 25, 27, 29-31, 33 two randomised trials26, 28 and two randomised 
crossover trials.23, 32 The length of intervention ranged from 15 days to 24 weeks and the 
frequency of intervention ranged from twice weekly to daily. Eight studies did not follow up 
participants after the intervention period19-24, 27-29, 32, 33 and four studies included a follow up 
assessment at 4,31 8,25 1030 and 18 weeks26 after the intervention had ended (Table 3).  
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Six studies investigated physiotherapy as part of a multi-dimensional intervention21, 22, 26-28, 
30, 33 and seven studies investigated the use of only a physiotherapy intervention.19, 20, 23-25, 29, 
31, 32 Study sample sizes ranged from 6-111 participants, EDSS scores ranged from 1.5-9.5. 
Eight studies included participants with both SPMS and PPMS21-24, 27, 31-33 and five studies 
included only participants with SPMS.19, 26, 28-30 There were no studies that included only 
participants with PPMS (Table 3). There were 45 outcome measures used across the 15 
articles with few instances of commonality despite often measuring the same symptom or 
functional status. Baseline measurements of all outcome measures and final values or 
change values for the main findings of each study can be found in supplementary Table S1. 
 
Interventions 
 
There were four instances when the same type of intervention was implemented: 
physiotherapy as part of a multi-disciplinary rehabilitation intervention was investigated by 
two studies,21, 22, 33 Functional Electrical Stimulation (FES) was investigated by two studies,19, 
20, 28 exercise therapy was investigated by three studies,24, 25, 27 and a combination of 
botulinum toxin type A (BTX-A) injections and manual stretches was investigated by two 
studies.26, 30 The following interventions were investigated by one study each: 
acupuncture29; inspiratory muscle training31; Body Weight Supported Treadmill Training 
(BWSTT) and robotic orthotics32 and therapeutic standing using a standing frame.23 
 
Physiotherapy as part of a multi-disciplinary rehabilitation programme 
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The evidence is positive regarding the efficacy of a six week multi-disciplinary rehabilitation 
programme for the rehabilitation of people with progressive MS. The two studies (described 
in three articles) which used multi-disciplinary rehabilitation programmes found 
improvements in disability when measured using the Functional Independence Measure, 
however the EDSS level remained unchanged.21, 22, 33 Improvements were also found in 
depression, social experience, quality of life and fatigue and these were maintained at six 
weeks post intervention21, 22 (Table 3). The multi-disciplinary rehabilitation programmes 
differed both in delivery setting and the control group interventions, however both had 
positive effects.  
 
Functional Electrical Stimulation 
 
The evidence is conflicting regarding the efficacy of using FES as an intervention for the 
rehabilitation of people with progressive MS. The two studies which used FES (described in 
three articles) found positive results for an orthotic effect and decrease in falls with FES in 
comparison to a home exercise plan aimed at improving core stability.19, 20, 28 However, 
Taylor et al. found their FES intervention produced a therapeutic effect in gait quality, while 
Barret et al. found only their home exercise plan produced a therapeutic effect on walking 
speed and endurance. These conflicting results may be due to differences in duration of the 
interventions, the control group interventions and the use of gluteal stimulation in addition 
to peroneal FES by Taylor et al. (Table 3). 
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Exercise therapy 
 
The evidence is inconclusive regarding the efficacy of using exercise therapy for the 
rehabilitation of people with progressive MS. Two of the three studies which used exercise 
therapy investigated endurance training in a clinical environment24, 27 and the third 
investigated resistance training and functional exercises in a home environment.25 The two 
endurance studies measured fitness and found improvements but only Briken et al. 
reported a significant improvement.24, 27 Briken et al. also reported significant 
improvements in mobility, depression, fatigue and cognitive function and Miller et al. 
reported significant improvements in muscle strength and anxiety. There was no significant 
improvement in any of the other outcomes of these studies (Table 3). Differences in results 
between these studies may be due to differences in inclusion criteria and the intervention 
protocol.  Skjerbaek et al. and Miller et al. included participants with a higher level of 
disability (EDSS 6.5-8.0) while Briken et al. included participants with a moderate disability 
(EDSS 4-6). Skjerbaek et al. and Briken et al. conducted their final assessments at four and 
six weeks respectively without a follow up assessment while Miller et al. did a follow up 
assessment eight weeks after their eight week intervention (Table 3). 
 
Botulinum toxin type A injections and manual stretches  
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The evidence in this review is positive regarding the efficacy of using a combination of BTX-A 
injections and manual stretches for the rehabilitation of people with progressive MS. 
However, it is unclear which combination is the most effective. The two studies which used 
BTX-A injections and manual stretches differed as Giovanelli et al.30 compared BTX-A 
injections to BTX-A injections and manual stretches whilst Paolini et al.26 conducted a three 
arm randomised trial investigating different combinations of BTX-A injections, manual 
stretches and segmental muscle vibration (Table 3). Each group experienced improvements 
in spasticity, with those who only received BTX-A injections experiencing the least 
improvement.30 Significant improvements were also found in subjective relief of 
symptoms,30 fatigue and activities of daily living26 in those who received a combination of 
BTX-A injections and manual stretches, however improvements in spasticity were not 
maintained at 18 weeks post intervention compared to six weeks post intervention.26 In 
contrast, interventions incorporating segmental muscle vibration also produced significant 
improvements in spasticity however these improvements were maintained at follow up 
assessments26 (Table 3). 
 
Acupuncture 
 
The evidence is inconclusive regarding the efficacy of acupuncture for the rehabilitation of 
people with progressive MS. There was only one study that investigated Chinese Medical 
acupuncture in comparison to minimal acupuncture29 (a form of sham acupuncture where 
needles are inserted to a shallower depth and not at true acupuncture points34). Minimal 
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acupuncture produced significant improvements in the psychological sub-score of the 
Multiple Sclerosis Impact Scale compared to Chinese Medical acupuncture.  No changes 
were seen in any other outcomes (Table 3).   
 
Inspiratory muscle training 
 
The evidence in this review is positive regarding the efficacy of using inspiratory muscle 
training for the rehabilitation of people with progressive MS, although only one study was 
found which investigated this technique. The study investigated the use of an inspiratory 
muscle trainer in comparison to deep breathing exercises.31 A significant improvement was 
found in maximal inspiratory pressure and maximal expiratory pressure in those using the 
inspiratory muscle trainer. No changes were seen in any other outcomes (Table 3).  
 
Body Weight Supported Treadmill Training and robotic orthotics 
 
The evidence in this review is inconclusive regarding the efficacy of BWSTT and robotic 
orthotics for the rehabilitation of people with progressive MS. Only one study investigated 
BWSTT compared to BWSTT and robotic orthotics in a randomised crossover trial.32 There 
was a trend towards improvement in double-limb support time in those receiving BWSTT 
compared to those receiving BWSTT and robotic orthotics. At the end of the study, all 
participants showed significant improvements in walking speed, endurance, double limb 
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support time and disability but not in step length ratio (Table 3). However, after the 
washout period, values had not returned to baseline. Therefore between group analyses 
were performed after the initial three week intervention period. 
 
Therapeutic standing 
 
Similar to other physiotherapeutic interventions only one study investigated the efficacy of 
therapeutic standing for the rehabilitation of people with progressive MS. The use of a 
standing frame was compared to a daily home exercise programme consisting of abdominal 
crunches, hip rolls, lumbar rolls and bridging.23 Therapeutic standing produced significant 
improvements in passive hip and ankle range of motion and a trend towards improvement 
in ankle spasticity; while the home exercise programme resulted in trends towards 
improvement in frequency of leg spasms (Table 3).   
 
Overall outcome of studies 
 
Generally the articles presented a positive effect of physiotherapy for the rehabilitation of 
people with progressive MS. Thirteen studies (described in 15 articles) found that the 
intervention group improved more than the comparison or control group in at least one 
outcome measure.19-25, 27, 30, 31, 33 One study only found statistically significant improvements 
in within group analysis,26 one study reported that neither group made an improvement 
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large enough for statistical significance27 and one study found that participants who 
received the control treatment improved more than those who received the intervention.29 
It is important to note that only one study used a power calculation to determine the 
required sample size however due to ‘drop outs’ the results were subsequently 
underpowered.  
 
Clinical significance of improvements 
 
From the papers included in this review, where a statistically significant change in the 
outcome measure was reported data detailing minimal clinically important differences 
(MCID) in people with MS was sought. Only four outcome measures had MCID data 
available; the timed 25 foot walk test (improvement of 17.2%),35 the six minute walk test 
(improvement of 21.6 m),36 the fatigue impact scale (improvement of 10-20 points)37 and 
the physical sub-score of the multiple sclerosis impact scale (improvement of 8 points).38 
Four studies had statistically significant results that used at least one of these outcome 
measures (Table 4).22, 24, 28, 32 All of these results were above the level of MCID for people 
with MS indicating a positive perspective for using physiotherapy in the rehabilitation of 
people with progressive MS. The four trials used four different interventions; 
multidisciplinary rehabilitation,22 FES,28 exercise therapy24 and BWSTT and robotic 
orthotics.32 Three trials included participants who were moderately affected by MS (EDSS 
levels 4-6.5)24, 28, 32 and one had a wider range and included those more severely affected 
(EDSS levels 4-8)22 (Table 4). Two of the studies used the fatigue impact scale,22, 24 both 
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produced similar levels of change despite Patti et al.22 including participants with a wider 
EDSS range and higher levels of fatigue at baseline. Similarly, two studies used the six 
minute walk test,24, 32 both produced similar improvements despite differences in distance 
walked at baseline.  
 
Discussion 
 
Overall the evidence presented in this review is positive regarding the efficacy of 
physiotherapy for the rehabilitation of people with progressive MS although it should be 
noted that the evidence is generally weak due to the variation in interventions and a lack of 
power within studies.   
The Progressive MS Alliance, and previous reviews, have highlighted that research regarding 
progressive MS and higher levels of disability is an area requiring further work.5, 13, 15 Only 
four studies within the review included participants with a high level of disability (EDSS > 
6.5) (n=62), five studies did not make a distinction in the level of disability of their 
participants (n=242) and four studies included only participants with a mild to moderate 
level of disability (EDSS < 6.0) (n=178). Exercise therapy was the only intervention where the 
effects were compared across disability levels.25, 26, 30 The results of these studies agreed 
with those of previously published reviews which found exercise therapy produced 
improvements in fatigue in those with a mild to moderate disability,9 while no significant 
results were found in those with a higher level of disability.6 
Physiotherapy for progressive MS 
16 
 
The results of this review were consistent with those found in systematic reviews of the 
other interventions for either MS or similar patient groups. Previously published reviews 
investigating the efficacy of physiotherapy interventions for people with MS found that 
multi-disciplinary rehabilitation programmes increased participation (as a result of a 
decrease in disability) and quality of life39; were unable to draw a conclusion as to the 
effectiveness of acupuncture40; found respiratory muscle trainers increased maximal 
inspiratory and expiratory pressure41 and that BWSTT and BWSTT with robotic orthotics 
both improved walking speed, double-limb support time, endurance and step length ratio.42 
However there was no improvement in step length ratio in the study presented in this 
review. Two reviews assessing the efficacy of FES in chronic stroke found it had a good 
orthotic effect43  but were unable to conclude on the efficacy of a therapeutic effect.44 
Reviews assessing interventions for neurological impairments were unable to ascertain the 
most effective adjunct therapy to BTX-A injections in the treatment of spasticity45 and that 
therapeutic standing produced improvements in ankle range of motion.46 However, the 
similarity between the results of this review and other reviews for the same interventions in 
similar patient groups such as RRMS should be approached with caution due to the 
previously mentioned methodological weaknesses in the body of evidence presented. 
Symptom management and rehabilitation is one of the five key research priorities identified 
by the Progressive MS Alliance.5 However, impact on quality of life and participation should 
also be a consideration.  Thus, identifying the patient groups who would experience the 
greatest improvement in clinical outcomes to particular interventions, with the greatest 
impact upon quality of life and participation, would help establish the full effectiveness of 
interventions. 
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Study limitations 
  
This review was limited to only include articles in published in English. It was further limited 
by the broad spectrum of physiotherapy as a discipline which led to variation in duration, 
dose, intensity and the type of interventions included. 
 
Future Work 
 
We recommend future work should be carried out to investigate physiotherapy 
interventions for people with progressive MS using adequately powered randomised trials 
with an appropriate control, long term follow up and adequate reporting.47 Studies should, 
where possible, aim to use a core set of outcome measures48 and use outcome measures for 
which there is available data of MCID for people with MS. Future research should also 
consider participants with PPMS and SPMS separately to investigate whether this has an 
effect on clinical outcomes. We also recommend investigation to ascertain which patient 
groups would experience largest improvements in quality of life from improvements in 
clinical outcomes. 
 
Conclusion 
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In conclusion, the evidence within this review demonstrates that physiotherapy may be 
effective in the rehabilitation of people with progressive MS. This review which focussed on 
people with progressive MS had similar findings to reviews in similar patient groups.   
Further investigation, with appropriately powered studies and consistency in outcome 
measures between studies is required to strengthen this evidence base and conduct meta-
analyses of the evidence.    
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Table 1. Search strategies for electronic databases.  
Database Search Strategy 
Cochrane library (Progressive near/2 ("multiple sclerosis" or MS)) AND ((MeSH descriptor: [Physical 
Therapy Modalities] explode all trees) OR(MeSH descriptor: [Rehabilitation] explode all 
trees) OR (MeSH descriptor: [Exercise] explode all trees) OR (MeSH descriptor: 
[Resistance Training] explode all trees) OR (MeSH descriptor: [Transcutaneous Electric 
Nerve Stimulation] explode all trees) OR (MeSH descriptor: [Electric Stimulation] explode 
all trees) OR(MeSH descriptor: [Acupuncture] explode all trees)) 
 
Web of Science 
Core Collections 
((progressive NEAR/2 (MS OR "Multiple Sclerosis")) AND ((physiotherap* OR "physical 
therapy") OR (rehabilit*) OR (exercise OR training) OR ("electrical stimulation" OR FES 
OR NMES OR TENS OR "neuromuscular stimulation") OR (acupuncture)  
 
Embase via Ovid ((progressive adj2 ("multiple sclerosis" or MS)).mp.) AND ((home physiotherapy OR 
physiotherapy) OR (prevention OR rehabilitation OR therapy OR rehabilit*.mp. OR 
rehabilitation center OR rehabilitation care OR breathing exercise OR muscle exercise OR 
arm exercise OR treadmill exercise OR aerobic exercise OR static exercise OR leg exercise 
OR isokinetic exercise OR closed kinetic chain exercise OR open kinetic chain exercise OR 
exercise.mp. OR exercise tolerance OR isometric exercise OR isotonic exercise OR 
aquatic exercise OR dynamic exercise OR stretching exercise OR anaerobic exercise OR 
exercise OR nerve stimulation OR electrostimulation therapy OR electroacupuncture OR 
functional electrical stimulation OR neuromuscular electrical stimulation OR 
transcutaneous nerve stimulation OR acupuncture OR acup.mp. electrostimulation OR 
functional electrical stimulation OR muscle OR gait) 
 
MEDLINE via 
OVID 
((progressive adj2 ("multiple sclerosis" or MS)).mp.) AND (exp Exercise Therapy  
physiotherapy.mp. OR physical therapy.mp. OR rehabilitation OR "activities of daily 
living" OR exercise therapy OR motion therapy, continuous passive OR muscle stretching 
exercises OR plyometric exercise OR resistance training OR rehabilitation, vocational OR 
exp Exercise Therapy OR exp Plyometric Exercise OR exercise.mp. OR exp Exercise 
Movement Techniques OR exp Exercise OR Electric Stimulation OR electric stimulation 
therapy OR electroacupuncture OR spinal cord stimulation OR transcutaneous electric 
nerve stimulation OR Transcutaneous Electric Nerve Stimulation OR exp Acupuncture 
Therapy OR exp Acupuncture Analgesia OR exp Acupuncture OR acupuncture.mp.) 
 
Pedro “progressive AND multiple AND sclerosis” 
 
 
Physiotherapy for progressive MS 
28 
 
 
Table 2. PEDro scores for included studies.   
Author 
Eligibility 
Criteria* 
Random 
allocation 
Concealed 
allocation 
Baseline 
comparability 
Participant 
blinding 
Therapist 
blinding 
Assessor 
blinding 
<15% 
dropout 
Intention
-to-treat 
Between-
group 
difference 
Point 
Estimate 
and 
Variability 
Total 
(0-10) 
Freeman et al.33  Y Y Y Y N N N Y N Y Y 6 
Patti et al.21† Y Y Y Y N N Y Y Y Y Y 8 
Patti et al.22† Y Y Y Y N N Y Y Y Y Y 8 
Klefbeck and 
Hamrah Nedjad31 
Y Y N Y N N N Y N Y Y 5 
Baker et al.23 Y Y N N N N Y Y Y Y Y 6 
Giovanelli et 
al.30‡ Y Y Y Y N N Y Y N Y Y 7 
Donnellan & 
Shanley29 
Y Y Y Y Y N Y Y Y Y Y 9 
Lo & Triche32 Y Y N Y N N N Y Y Y Y 6 
Barrett et al.19§ Y Y Y Y N N N N N Y Y 5 
Esnouf et al.20§ Y Y Y Y N N Y N N Y Y 6 
Miller et al.25 Y Y Y Y N N Y Y Y Y Y 8 
Paoloni et al.26 Y Y Y Y N N Y Y Y Y Y 8 
Taylor et al.28 Y Y Y Y N N Y N N Y Y 6 
Briken et al.24 Y Y Y Y N N N Y Y Y Y 7 
Skjerbaek et al.27  Y Y Y Y N N Y Y N Y Y 7 
EC assessed all articles,19-33 LP assessed 8 articles19, 20, 23-26, 32, 33 and EHC assessed 8 articles.21, 22, 26-31 
*No point awarded for stating eligibility criteria. 
†Patti et al. 2002 and Patti et al. 2003 described the same study. 
‡All three reviewers rated this paper initially and discussed results to ensure consistency. 
§ Barrett et al. 2009 and Esnouf et al. 2010 described the same study. 
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Table 3. Evidence table 
Author, 
date and 
design 
Sample size 
PPMS 
SPMS 
EDSS range 
Drop outs 
Intervention, duration, length 
of session, frequency 
Comparison/ 
control 
Time 
Points 
(weeks) 
Outcome measures* Main findings* 
Freeman et 
al.33 1997 
RCT 
n=66 
PPMS (n=6) 
SPMS (n=60) 
EDSS 5.0-9.5  
Drop out: 4 (6%) 
6 weeks, MDT in-patient 
rehabilitation, 45 min, 2/week 
(n=32) 
 
Wait list control 
(n=34) 
0, 6 Pri: EDSS, FIM, LHS Between group:  
FIM (p<0.001), LHS (p<0.01) 
Patti et al.22 
2002 
RCT 
n= 111 
PPMS (n=23) 
SPMS (n=88) 
EDSS 4-8 
Drop out: 13 
(12%) 
12 weeks: 6 week MDT out-
patient rehabilitation, 50-60 
min, 6/week, followed by 6 
week HEP, 60 min, 5/week 
(n=58) 
 
HEP for 12 weeks  
(n=33) 
0, 6, 12 Pri: EDSS, SF-36  
Sec: BDI, SET, FIS 
Between group:  
SF-36: RE subscale (p<0.005) all other 
subscales (p<0.001), BDI(p<0.001), SET 
(p<0.001), FIS (p<0.001) 
Patti et al.21 
2003 
RCT 
As above As above 
 
As above 
 
As above Pri: FIM  
Sec: EDSS 
Between group: 
FIM (p<0.001) 
 
Klefbeck 
and Hamrah 
Nedjad31 
2003 
RCT 
n=15 
progressive MS 
EDSS 6.5-9.5  
Drop out: 1 (7%) 
10 weeks: Inspiratory muscle 
trainer, 3 sets of 10 repetitions, 
twice every second day (n=7) 
 
Normal treatment 
which had deep 
breath exercises, 
regular phone 
calls (n=8) 
0, 10, 14 Pri: VC, FVC, FVC%, FEV 
FEV%, Max insp 
pressure, Max exp 
pressure, FSS, Borg 
scale 
Between group: 
Max insp pressure (p<0.01) 
Within group: 
I: max exp pressure (p<0.02) 
Baker et 
al.23 2007 
Randomised 
crossover 
design 
n= 6 
progressive MS 
EDSS > 7  
Drop out: 0 (0%)  
3 weeks: Standing frame,30 
min/day (n=3) 
 
I+C swapped after 3 weeks (no 
washout period) 
HEP of abdominal 
crunches, 
bridging, pelvic 
and lumbar rolls, 
5 repetitions of 8 
exercises (n=3) 
0, 3, 6 Pri: Ashworth Scale, 
Spasm frequency, 
Resting ROM in supine 
Between group: 
Resting ROM in supine: L ankle (p=0.020), 
R ankle (p=0.026), L hip (p=0.039), R hip 
(p=0.020) 
Within group: 
I: Ashworth scale, R ankle (p=0.08), L ankle 
(p=0.08) 
C: spasm frequency, R leg (p=0.06) 
Giovanelli et 
al.30 2007 
n=38  
All SPMS 
15 days: I: BTX-A injection in 
either upper limb (FDS, FCU, 
BTX-A injection 
only (n=28) 
0, 2, 4, 
12 
Pri: MAS, VAS of relief 
from spasticity in 
Between group: 
MAS (p<0.01), VAS (p<0.01) 
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RCT EDSS 3-7.5  
Drop out: 2 (5%) 
FCR) or lower limb (tibialis 
posterior, gastrocnemius, 
soleus) followed by 40min/day 
of passive movements to 
prevent muscle contractures 
(n=20) 
injected muscle  
Donnellan & 
Shanley29 
2008 
RCT 
n=14  
All SPMS 
EDSS 1.5-7.0  
Drop out: 1 (7%)  
5 weeks: Chinese medical 
acupuncture, 2/week (n=7) 
 
Minimal 
acupuncture† , 5 
weeks, twice a 
week (n=7) 
0, 5 Pri: MSIS-29 phys, 
MSIS-29 psych  
Sec: FSS, GHQ-12 
Between group (C vs I):  
MSIS-29 psych sub-score I (p=0.04) 
 
Lo & 
Triche32 
2008 
Randomised 
crossover 
design 
n=13  
PPMS (n=5) 
SPMS (n=8) 
EDSS 4.9 SD 1.2  
Drop out: 0 (0%) 
12 weeks: BWSTT, 3 weeks, 
2/week, 40 min, followed by 6 
week washout then BWSTT and 
robot orthotics a/a (n=6) ‡  
 
Same as I but 
BWSTT and robot 
orthotics first 
(n=7) 
0, 3, 9, 
12 
 
Pri: EDSS, Timed 25 
foot walk, 6 min walk, 
DST  
Sec: step length ratio  
Between group: 
DST: (p=0.06) 
Within group: 
Whole sample: timed 25 foot walk 
(p=0.0002), 6 min walk (p=0.002), DST 
(p=0.0007) and EDSS (p=0.001) 
Barrett et 
al.19 2009 
RCT 
n=53 
All SPMS 
EDSS 4-6.5 
Drop out: 7 
(13%)  
18 weeks, Peroneal  FES, worn 
in daily life (n=20) 
 
HEP of trunk and 
pelvic stability 
and lower limb 
strength, balance 
and control 
exercises, 18 
weeks, 1-2/ day, 
30 min (n=24) 
0, 6, 12, 
18 
Pri: 10 m walk speed 
Sec: 3min walk 
distance 
 
 
 
Within group: 
I with FES vs I without: 10 m walk speed 
(p=0.001), 3 min walk distance (p=0.004)  
C: 10 m walk speed (p=0.001) 
C: 3 min walk distance (p=0.005) 
 
Esnouf et 
al.20 2010 
RCT 
n= 64 
All SPMS 
EDSS 4-6.5  
Drop out: 11 
(17%) 
As above (n=32) As above (n=32) 0, 18 Pri: COPM 
performance and 
satisfaction scores, 
Number of falls  
Between group: 
COPM performance (p=0.0038), 
satisfaction (p=0.007) 
Falls (p=0.036) 
Miller et 
al.25 2011 
RCT 
n= 30  
PPMS (n=11) 
SPMS (n=19) 
EDSS 6.5-8  
Drop out: 2 (7%) 
8 weeks, Domiciliary 
physiotherapy, 60 min, 2/week 
(n=15) 
 
Wait list control 
(n=15) 
0, 8, 16 Pri: MSIS-29 
Sec: EDSS, FIM, 
MSQoL, MS-RS, BPI, 
HADA, HADD, 
Dynamometry, 10 m 
walk, timed sit to stand 
Between group: 
R knee extensor strength(p=0.018), L knee 
flexor strength (p=0.006), R knee flexor 
strength (p=0.001), HADA (p=0.014) 
Paolini et n= 42 4 weeks: 3/week - 0, 10, 22 Pri: MAS, FSS, Barthel Within group: 
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al.26 2013 
RT (3 armed 
trial) 
All SPMS  
EDSS 2-6  
Drop out: 0 (0%) 
G1:  60 min passive movements 
to prevent contractures + 30- 
min SMV (n=14) 
G2:  BTX-A injection 2 weeks 
before study then same as G1 
(n=14)  
G3: BTX-A injection 2 weeks 
before study and 60 min 
passive movements same as G1 
(n=14) § 
index G1: Knee MAS (p<0.001), ankle MAS 
(p<0.001), FSS (p=0.004) 
G2: Knee MAS (p<0.001), ankle MAS 
(p<0.001), FSS (p=0.05) 
G3: Knee MAS (p<0.001), ankle MAS 
(p<0.001), Both knee and ankle MAS 
higher at 22 weeks than 10 weeks 
(p<0.05), FSS (p=0.02), Barthel index 
(p=0.004) 
 
Taylor et 
al.28 2013 
RT 
n= 25 
All SPMS  
EDSS 4-6.5 
Drop out: 5 
(20%) 
24 weeks: Weeks 1-6: peroneal 
FES worn in daily life,  
Weeks 7-12: addition of gluteal 
FES  
weeks 13-18: eight sessions of 
core stability physiotherapy and 
HEP of core stability exercises, 
weeks 19-24 continue with HEP  
FES wear continued for second 
12 weeks (n=11) 
Same as I but 
with 
physiotherapy 
and HEP first 
followed by FES 
(n=14) 
-4, 0, 6, 
12, 18, 
24 
Pri: ROGA, 10 m walk 
speed, MSIS-29, Falls 
frequency  
Between group: 
ROGA: Without FES week 24 (p=0.044), 
with FES week 18 (p=0.028) 
Within group: 
I: MSIS-29 psych week 18 (p<0.05), MSIS-
29 phys week 24 (p<0.05), 10 m walk 
speed with peroneal FES (p=0.06) and 
gluteal FES (p=0.06), falls frequency 
(p<0.05) 
C: 10 m walk speed with FES vs no FES 
(p<0.05), MSIS-29 phys week 24 (p<0.05), 
falls frequency (p<0.05) 
Briken et 
al.24 2014 
RCT (4 
armed trial) 
n= 47  
PPMS (n=11) 
SPMS (n=31) || 
EDSS 4-6  
Drop out: 5 
(11%) 
10 weeks, 15-45 min (Borg 2-3), 
2-3/week 
Three groups: Arm ergometry 
(n=12), Rowing (n=12) and 
Cycling (n=12) § 
 
 
Wait list control 
n=11 
0, 10 
 
Pri: VO2 peak, 6 Min 
walk, VLMT, IDS, FIS 
Between group: 
Cycle group vs C: VO2 peak (p=0.003), 6 
Min walk test (p=0.005), VLMT (p=0.009), 
depression (p=0.035). 
Arm group vs C: 6 Min walk test (p=0.003), 
VLMT (p=0.007), fatigue (p=0.013), IDS 
(p=0.001). 
Rowing group vs C: VLMT (p=0.001) 
Skjerbaek et 
al.27 2014 
RCT 
n=11 
PPMS (n=3) 
SPMS (n=8) 
EDSS 6.5-8.0  
Drop out: 1 (9%) 
4 weeks: 10 sessions, 
Endurance training: 
predominantly UL exercises (6 x 
3 min at target heart rate (65-
75% HRmax) and standard in-
patient rehabilitation (n=6). 
Standard in-
patient 
rehabilitation 
(n=5) 
0, 4 Pri: VO2 peak, MDI, 
MSIS-29, 9HPT, HGT, 
BBT, 6minWCT 
Between group: 
VO2 peak (p=0.06) 
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Abbreviations: 6minWCT: 6 minute wheelchair test, 9HPGT: 9 hole peg test, BBT: box and block test, BDI: beck depression inventory, Borg: the borg scale of perceived 
exertion, BPI: brief pain inventory, C: control group, COPM: Canadian occupational performance measure, DST: double-limb support time,  
FCR: flexor carpi radialis, FCU: flexor carpi ulnaris, FDS: flexor digitorum superficialis, FEV: Forced expiratory volume, FEV%:  forced expiratory volume in percentage of FVC, 
FIM: functional independence measure, FIS: fatigue impact scale, FSS: fatigue severity scale, FVC: forced vital capacity, FVC%: forced vital capacity percentage predicted,  
GHQ-12: general health questionnaire 12, HADA: hospital anxiety and depression scale anxiety sub-scale, HADD: hospital anxiety and depression scale depression sub-
scale, HEP: home exercise plan, HGT: hand grip test, HRmax: heart rate max, I: intervention group, IDS: inventory of depressive symptoms, L: left, LHS: London handicap 
scale, m: metre, MAS: modified ashworth scale, max exp: maximal expiratory, max insp: maximal inspiratory, MDI: major depression inventory, MDT: multi-disciplinary 
team, min: minutes, MSIS-29: multiple sclerosis impact scale, MSIS-29 phys: multiple sclerosis impact scale physical subscale, MSIS-29 psych: multiple sclerosis impact scale 
psychological subscale, MSQoL: Leeds multiple sclerosis quality of life scale, n: sample size, Pri: primary outcome measures, R: right, RCT: randomised controlled trial, RE: 
role functioning emotional sub-scale, ROGA: Rivermead observational gait analysis, ROM: range of motion, RT: randomised trial, Sec: secondary outcome measures, SET: 
Tempelaar social experience checklist, SF-36: short form 36 health survey, SMV: segmental muscle vibration, UL: upper limb, VAS: visual analogue scale, VC: vital capacity, 
VLMT: verbal learning memory test, VO2 peak: peak oxygen uptake. 
*Baseline values of all outcome measures and final values/magnitude of changes can be found in supplementary table 1. 
† Minimal acupuncture: a form of sham acupuncture where needles are inserted to a shallower depth and not at true acupuncture points (MacPherson et al., 2002).   
‡ Groups did not return to baseline after 6 week washout period so analysis conducted after end of first trial.   
§ Intervention group referred to as “I” throughout apart from studies by Paolini et al. and Briken et al where the three experimental arms are referred to as “G1”, “G2” and 
“G3” and “Arm ergometry”, “Rowing” and “Cycling” respectively. 
|| Characteristic data of drop outs not supplied. 
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Table 4. Statistically significant results of outcome measures with available data of MCID for people with MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 6minWT: six minute walk test, Arm: arm ergometry group, C: control group, FIS: fatigue impact scale (maximum score: 160), I: intervention group, MCID: 
minimal clinically importance difference, MDT: multi-disciplinary, MSIS-29: multiple sclerosis impact scale (maximal physical sub-score: 80), T25fWT: timed 25 foot walk 
test 
All baseline and change/final values are mean (SD) 
*Change values 
† Between group analysis 
‡ Final values   
§ Within group analysis 
||17.2% improvement is a change in speed.35 Lo & Triche presented results in seconds.32 Means of baseline and change in speed calculated from raw time data equated to 
a 40% improvement in speed.  
  
Author 
EDSS 
Intervention Outcome 
Measure  (MCID) 
Baseline values Change values/ Final values 
Patti et al.22 
4-8 
MDT out-
patient 
rehabilitation 
FIS (10-20 points) I: 116.8 (40.9)  
C: 127.0 (36.0) 
I: -18.8 (14.3)*  
C: 0.6 (0.9)* (p<0.001)† 
Taylor et al.28 
4-6.5 
FES MSIS-29 physical 
sub-score (8 
points) 
I: 48.8(30.6-55.0)  
C: 46.3(16.3-56.3) 
I: 26.3(16.2-38.1)‡ (p<0.05)§ 
C: 35.0(21.3-51.3)‡ (p<0.05) § 
Briken et al.24 
4-6 
Exercise therapy 6minWT (21.6 m) 
 
 
 
FIS (10-20 points) 
Cycling: 288.65 m (99.3) 
Arm: 296.79 m (123.79) 
Rowing: 306.61 m (103.69)  
C: 325.92 m (117.35) 
Cycling: 35.00(18.07)  
Arm: 45.00(14.73)  
Rowing: 35.27(13.86) 
C: 38.00(15.15) 
Cycling: 344.97(118.30)‡ 
C: 319.49(109.49)‡ (p=0.005)† 
Arm: 360.03(154.64)‡ 
C: 319.49 (109.49)‡ (p=0.003)†  
Arm: 31.80(11.09)‡ 
C: 39.30(17.49)‡ (p=0.013)† 
Lo & Triche32 
Mean 4.9 (SD 1.2) 
BWSTT and 
robot orthotics 
T25fWT (17.2%)|| 
6minWT (21.6 m) 
whole sample: 9.9 s (4.2) 
whole sample: 220.3 m (96.5) 
whole sample: -3.1(2.4)* (p=0.0002)§ 
whole sample: 83.4(78.0)* (p=0.002)§  
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Figure 1. PRISMA flowchart of screening and inclusion process of included trials. 
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Supplementary table S1: Primary and secondary outcome measures with baseline values and main 
findings from each trial.   
Author, 
date and 
design 
Outcome measures and baseline values  Main findings [Intervention, Control]  
 
Freeman et 
al.33 1997 
RCT 
Pri: EDSS*: I: 6.5(5.0-9.0), C: 6.5(6.0-8.5) 
FIM*:  I: 67(13-87), C:  69.5(18-84) 
LHS†: I:  61.5(13), C:  66.2(8.74) 
Between group (Change values): 
FIM*: motor domain: 4.0(-10,19), 2.5(-16,5) 
(p<0.001), Self-care domain: 1.5(-5,9), -1.0(-9,3) 
(p<0.0001) 
LHS†: 2.9 (8.9), -2.7 (8.6)(p<0.01) 
Patti et al.22 
2002 
RCT 
Pri: EDSS†: I: 6.2(1.2), C: 6.1(1.2)  
SF-36 subscales:  
RE†: I: 56.1(40.4), C: 42.1(43.4),  
PF†: I: 39.3(23.0), C: 31.2(23.1),  
RP†: I: 36.9(36.2), C: 26.4(36.8),  
BP†: I: 58.2(26.0), C: 65.4(27.1),  
GH†: I: 49.9(21.1), C: 45.0(20.6),  
VT†: I: 47.8(17.5), C: 42.7(18.4),  
SF†: I: 59.8(21.5), C: 57.6(27.1),  
MH†: I: 54.2 (22.8), C: 53.4 (23.7) 
Sec: BDI†: I: 11.0(7.5), C: 12.5(7.6) 
SET†: I: 28.9(6.0), C: 29.3(5.9) 
FIS†: I: 116.8(40.9), C: 127.0(36.0) 
Between group (Change values): 
SF-36 subscales:  
RE†: 6.2(23.7), -0.1(0.3) (p<0.005),  
PF†: 6.91(18.1), -0.1(0.3) (p<0.001),  
RP†: 14(24.3), -0.2(0.5) (p<0.001),  
BP†: 14.9(20.0), -0.1(0.6) (p<0.001),  
GH†: 5.8(10.5), -0.2(0.5) (p<0.001), 
VT†: 7.4(12.5), -0.1(0.5) (p<0.001),  
SF†: 11.5(14.6), -0.1(0.3) (p<0.001), 
MH†: 7.7(15.8), -0.1(0.5) (p<0.001) 
BDI†: -2.2(3.4), 0.1(1.0) (p<0.001), 
SET†: -2.6(6.0), -0.3(0.8)(p<0.001),  
FIS†: -18.8(14.3), 0.6(0.9) (p<0.001) 
Patti et al.21 
2003 
RCT 
Pri: FIM†: I: 92.9(11.0), C: 93.7(16.4)  
Sec: EDSS†: I: 6.2(1.2), C: 6.1(1.2) 
Between group (Change values): 
FIM†: 10.2(11.8): 0.0(0.7) (p<0.001) 
 
Klefbeck 
and Hamrah 
Nedjad31 
2003 
RCT 
Pri: VC (L)*: I: 2.4(0.5-3.4), C: 2.1(0.5-6.2) 
FVC (L)*: I: 2.7(1.0-3,4), C: 2.6(1.3-6.7) 
FVC%*: I: 78(36-93), C: 69(38-127) 
FEV (L)*: I: 2.2(1.0-3.3), C: 2.3(1.3-5.0) 
FEV%*: I: 83(82-100), C: 88(81-100) 
Max insp pressure (cmH20)*: I: 42(28-74), C: 
52(15-120) 
Max exp pressure (cmH20)*: I: 46(36-58), C: 
51(20-147) 
FSS*: I: 4.2(2.8-6.0), C: 5.1(2.0-6.7) 
Borg scale*: I: 14(9-17), C: 14(10-17) 
Between group (Final values): 
Max insp pressure*: 67(55-100),C: 54(10-126) 
(p<0.01) 
Within group (Final values): 
I: max exp pressure*: 63(44-80) (p<0.02) 
 
Baker et 
al.23 2007 
Randomised 
crossover 
design 
Pri: Ashworth Scale*: whole sample: R hip 
flex: 1.5(1-3), L hip flex: 2.0(1-2), R hip abd: 
1.0(1-3), L hip abd: 2.0(1-2), R knee: 1.5(2-
3), L knee: 2.0(2-3), R ankle: 2.0(2-3),  
L ankle: 2.0(2-3)  
Spasm frequency*: whole sample: R: I: 
2.0(0-4), L: I: 2.0(0-4) 
Resting ROM in supine*: whole sample: R 
ankle: 10(10-12), L ankle: 13.5(10-15), R 
knee: 2.5(0-5), L knee: 2.0(0-2), R hip: 10(0-
10), L hip: 20(5-20) 
Between group (Final values): 
Resting ROM in supine*:  
R ankle: 5.0(-5-7), 10(7-12) (p=0.020),  
L ankle: 2.5(0-7), 10(10-15) (p=0.026),  
R hip: 0.0(0-5), 10(5-15) (p=0.020),  
L hip: 5.0(0-10), 10(5-10) (p=0.039) 
Within group (Final values): 
I: Ashworth scale*:  
R ankle: 2.0(1-3) (p=0.08),  
L ankle: 1.5(1-3) (p=0.08) 
C: spasm frequency R leg*:  
1.0(0-4) (p=0.06) 
Giovanelli et 
al.30 2007 
RCT 
Pri: MAS†: I: 3.63(0.49), C: 3.61(0.50) 
VAS of relief from spasticity in injected 
muscle, week 2: I: 5.18 (1.10), C: 5.50(1.38) 
Between group (Change values): 
MAS†: -0.95(0.78), -0.28(0.46) (p<0.01)  
VAS of relief from spasticity in injected 
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muscle†: 2.68(1.08), 1.06(1.16) (p<0.01) 
Donnellan & 
Shanley29 
2008 
RCT 
Pri: MSIS-29 phys†: I: 55.2(23.6), C: 
57.7(23.8)  
MSIS-29 psych†: I: 34.3(23.7), C: 48.4(30.0) 
Sec: FSS†: I: 4.6(2.4), C: 2.8(1.9) 
GHQ-12†: I: 15.8(9.9), C: 17.7(9.5) 
Between group (Change values, C vs I): 
MSIS-29 psych†: 23(21.0), 6.0(13.9) (p=0.04) 
 
Lo & 
Triche32 
2008 
Randomised 
crossover 
design 
Pri: EDSS†: whole sample: 4.9(1.2)  
25 foot walk (s)†: whole sample: 9.9(4.2) 
6 min walk (m)†: whole sample: 220.3(96.5) 
DST(%): whole sample: 33.2(8.0) 
Sec: step length ratio†: whole sample: 
0.9(0.1) 
Between group (Change values): 
DST†: -7.1(3.9), -1.7(3.9) (p=0.06) 
Within group (Change values): 
25 foot walk†: 3.1(2.4) (p=0.0002)  
6 min walk†: 83.4(78.0) (p=0.002)  
DST†: -5.5(4.1) (p=0.0007)  
EDSS†: -1.0(0.7) (p=0.001) 
Barrett et 
al.19 2009 
RCT 
Pri: 10 m walk (ms-1)†: I: 0.79(0.35), C: 
0.68(0.28) 
Sec: 3 min walk (m)†: I: 99(44), C: 97(44) 
 
 
Within group (Final values): 
I with FES vs I without:  
10 m walk†: 0.80(0.35) (p=0.001) 
3 min walk†: 125 (55) (p=0.004)  
C: 10 m walk†: 0.77(0.29) (p=0.001) 
C: 3 min walk†: 113 (46)  (p=0.005) 
Esnouf et 
al.20 2010 
RCT 
Pri: COPM performance*: I: 3.5(1.75-5.0), C: 
3.4(2.2-5.6) 
COPM satisfaction*: I: 2.2(1.0-5.0), C: 
2.6(1.0-4.6) 
Number of falls: n/a 
Between group (Change values): 
COPM performance*: 1.1(0.1-2.0), 0.0(0.0-0.9) 
(p=0.0038)  
COPM satisfaction*: 1.7(0.3-2.7), 0.0(0.0-1.0) 
(p=0.007) 
Number of falls (final values)*: 5, 18 (p=0.036) 
Miller et 
al.25 2011 
RCT 
Pri: MSIS-29†: I: 89.9(22.8), C: 82.8(17.3) 
Sec: EDSS†: I: 7(0.5), C: 7.1(8.1) 
FIM†: I: 68.9(12.9), C: 72.2(14.2) 
MSQoL†: I: 11.9(5.3), C: 8.3(5.3) 
MS-RS†: I: 32.7(13.9), C: 27.9(9.4) 
BPI†: I: 26.7(27.7), C: 25.6(17.7) 
HADA†: I: 6.0(5.7), C: 3.1(2.1) 
HADD†: I: 5.8(3.3), C: 6.3(3.6) 
Dynamometry (kg)†: R knee ext: I: 10.0(5.9), 
C: 9.3(6.0), R knee flex: I: 9.7(5.1), C: 
5.5(4.3), L knee ext: I: 7.2(5.1), C: 8.4(6.7), L 
knee flex: I: 7.7(6.0), C: 7.5(6.8) 
10 m walk (s): I: 41.2(32.9), C: 43.4(27.7) 
timed sit to stand (s): I: 6.2(2.3), C: 5.8(3.4) 
Between group (Change values): 
R knee ext strength†: 11.1(6.1), 8.4(6.7) 
(p=0.018)  
L knee flexor strength†: 6.9(5.3), 5.0(5.6) 
(p=0.006)  
R knee flexor strength†: 8.7(5.7), 4.8(4.2) 
(p=0.001) 
HADA†: 6.2(5.0), 3.8(4.0) (p=0.014) 
Paolini et 
al.26 2013 
RT (3 armed 
trial) 
Pri: Knee MAS ‡: G1: 3(3-4), G2: 4(3-4), G3: 
4(3-4)  
Ankle MAS‡: G1: 4(3-4), G2: 4(4-4), G3: 4(4-
4) 
FSS§: G1: 53.6(2.31), G2: 43.4(3.10), G3: 
48.5(2.77) 
Barthel index§: G1: 79.8(1.63), G2: 
76.4(2.95), G3: 77.5(1.50) 
Within group (Final values): 
G1: Knee MAS‡: 3(2-3) (p<0.001)  
Ankle MAS‡: 3(2-3) (p<0.001)  
FSS§: 46.7(2.75) (p=0.004) 
G2: Knee MAS‡:  3(2-3) (p<0.001)  
Ankle MAS‡:3(3-4) (p<0.001)  
FSS§: 39.7(2.97) (p=0.05) 
G3: Knee MAS‡: 3(2-4) (p<0.001)  
Ankle MAS‡: 4(3-4) (p<0.001)  
Knee and ankle MAS higher at 22 weeks than 
10 weeks: week 10 values: Knee MAS: 3(2-3) 
(p<0.05), Ankle MAS: 3(3-4) (p<0.05) 
FSS§: 42.5(2.17)(p=0.02)  
Barthel index§:  77.8(1.47)  (p=0.004) 
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Taylor et 
al.28 2013 
RT 
Pri: ROGA without FES‡: I: 13.0(8.5-21), C: 
15(11.5-17.5) 
10 m walk (ms-1)‡: I: 0.72(047-1.31), C: 
0.82(0.51-1.01)  
MSIS-29 phys‡: I: 48.8(30.6-55.0), C: 
46.3(16.3-56.3) 
MSIS-29 psych‡: I: 38.8(23.6-54.2), C: 
27.2(11.1-50.0) 
Falls frequency‡: I: 23.3(8.3-67.1), C: 
9.75(1.1-50.0) 
Between group (Final values): 
ROGA‡: Without FES week 24: 11(6-14.3), 
17(14.5-20) (p=0.044), with FES week 18: 
10(5.3-13), 12(10-16) (p=0.028) 
Within group (Final values): 
I: MSIS-29 phys‡: 26.3(16.2-38.1) (p<0.05), 
MSIS-29 psych‡: week 18: 19.4(9.7-27.3) 
(p<0.05)  
10 m walk‡: with peroneal FES: 1.2(0.72-1.27) 
(p=0.06), with peroneal and gluteal FES‡: 
1.04(0.76-1.27)(p=0.06) 
Falls frequency‡: 4(3.-7.75) (p<0.05) 
C: 10 m walk with peroneal and gluteal FES vs 
no FES‡: 0.89(0.64-1.09) (p<0.05),  
MSIS-29 phys‡: 35.0(21.3-51.3) (p<0.05)  
Falls frequency‡: 0.5(0.0-3.075) (p<0.05) 
Briken et 
al.24 2014 
RCT (4 
armed trial) 
Pri:VO2 peak (ml O2.min
-1)†:  
Cycling: 1490.18(528.20), Arm ergometry: 
1352.30(431.26), Rowing: 1306.00(421.79), 
C: 1377.40(325.19) 
Sec: 6 Min walk (m)†:  
Cycling: 288.65(99.3), Arm ergometry: 
296.79(123.79), Rowing: 306.61(103.69),  
C: 325.92(117.35) 
VLMT†: Cycling: 52.18(6.03), Arm 
ergometry: 46.80(10.22),  Rowing: 
51.09(10.42), C: 47.50(5.91) 
IDS†: Cycling: 18.36(12.27), Arm ergometry: 
21.10(10.24), Rowing: 13.91(7.82), C: 14.10 
(7.94),  
FIS†: Cycling: 35.00(18.07), Arm ergometry: 
45.00(14.73), Rowing: 35.27(13.86), C: 
38.00(15.15) 
Between group (Final values): 
Cycling vs C:  
VO2 peak†: 1253.70(297.33) (p=0.003)  
6 Min walk†: 344.97(118.30), 319.49(109.49) 
(p=0.005),  
VLMT†: 62. (7.18), 51.50(8.20)  (p=0.009) 
IDS: 14.73 (9.49), 18.40(10.36)  (p=0.035) 
Arm ergometry vs C: 
6 Min walk†: 360.03(154.64), 319.49 (109.49) 
(p=0.003)  
VLMT†: 58.10(8.48), 51.50(8.20) (p=0.007), 
FIS†: 31.80(11.09), 39.30(17.49)  (p=0.013),  
IDS†: 12.30(6.57), 18.40(10.36) (p=0.001). 
Rowing vs C:  
VLMT†:  63.09(9.94), 51.50(8.20) (p=0.001)  
Skjerbaek et 
al.27 2014 
RCT 
Pri: VO2 peak (ml O2.min
-1)†: I: 642(209), C: 
872(386)  
MDI†: I: 10.6(1.7), C: 14.6(7.3) 
MSIS-29†: I: 86(11.9), C: 76(20.5) 
9HPGT (s)†: I: 36.8(13.6), C: 66.9(61.7) 
HGT (N)†: I: 20.3(8.7), C: 19.9(10.3) 
BBT (blocks.min-1)†: I: 23.6(8.5), C: 27.0(8.4) 
6minWCT (m)†: I: 205(136), C: 313(71) 
Between group (Change values): 
VO2 peak†: 308(312), 2(29) (p=0.06) 
 
Abbreviations: 6minWCT: 6 minute wheelchair test, 9HPGT: 9 hole peg test, abd: abduction, BBT: box and 
block test, BDI: beck depression inventory, Borg: Borg rating of perceived exertion, BP: bodily pain, BPI: 
brief pain inventory, C: control group, COPM: Canadian occupational performance measure, DST: double-
limb support time, ext: extensor, FEV: Forced expiratory volume, FEV%:  forced expiratory volume in 
percentage of FVC, FIM: functional independence measure, FIS: fatigue impact scale, flex: flexion, FSS: 
fatigue severity scale, FVC: forced vital capacity, FVC%: forced vital capacity percentage predicted, GH: 
general health, GHQ-12: general health questionnaire 12, HADA: hospital anxiety and depression scale 
anxiety sub-scale, HADD: hospital anxiety and depression scale depression sub-scale, HGT: hand grip test, 
I: intervention group, IDS: inventory of depressive symptoms, L: left, LHS: London handicap scale, m: 
metres, MAS: modified ashworth scale, max exp: maximal expiratory, max insp: maximal inspiratory, MDI: 
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major depression inventory, MH: mental health, min: minutes, MSIS-29: multiple sclerosis impact scale, 
MSIS-29 phys: multiple sclerosis impact scale physical subscale, MSIS-29 psych: multiple sclerosis impact 
scale psychological subscale, MSQoL: Leeds multiple sclerosis quality of life scale, PF: physical functioning, 
Pri: primary outcome measure, R: right, RCT: randomised controlled trial, RE: role functioning emotional, 
ROGA: Rivermead observational gait analysis, ROM: range of motion, RP: role physical, RT: randomised 
trial, s: seconds, Sec: secondary outcome measures, SET: Tempelaar social experience checklist, SF: social 
functioning, SF-36: short form 36 health survey, VAS: visual analogue scale, VC: vital capacity, VLMT: 
verbal learning memory test, VO2 peak: peak oxygen uptake, VT: vitality. 
*Values are median(range). 
†Values are mean(SD). 
‡Values are median(interquartile range). 
§Values are mean(SE). 
